US Senate Passes Biosecure Act, Positive For Indian CDMO — Check Details
The US Senate on Friday passed the National Defense Authorisation Act which embedded an amended version of US Biosecure Act. The Biosecure Act aims to limit investment in sensitive Chinese industries.
The act mainly aims to safeguard American biotech and health data from foreign threats, particularly those posed by Chinese companies. The legislation aims to reduce US dependence on foreign labs and suppliers.
The Biosecure Act was first introduced in the US Senate in December 2023 and in the House in January 2024. It gained momentum and was passed by the House with bipartisan support in September 2024. However, the Senate blocked its inclusion in the National Defense Authorization Act (NDAA) for 2025 later that year. After revisions, the Act resurfaced in August 2025.
Divi's Labs
Syngene International
Neuland Labs
Jubilant Pharmova
Piramal Pharma
Laurus Labs
As US drug makers reduce dependence on Chinese players, Indian CDMOs (Contract Development and Manufacturing Organisations) are poised to capture new opportunities.
Laurus Labs: “This is being seen as a good step towards CDMO opportunities for Indian companies.”
Neuland Labs: “U.S. customers are looking at an alternative to China, so business is coming.”
Divi's Labs: “We are seeing a spike in opportunities coming our way."
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.